- Home
- CYRX vs ALLO Comparison
CYRX vs ALLO Comparison
Compare CYRX & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYRX
- ALLO
- Stock Information
- Founded
- CYRX 1999
- ALLO 2017
- Country
- CYRX United States
- ALLO United States
- Employees
- CYRX N/A
- ALLO N/A
- Industry
- CYRX Biotechnology: Pharmaceutical Preparations
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CYRX Health Care
- ALLO Health Care
- Exchange
- CYRX Nasdaq
- ALLO Nasdaq
- Market Cap
- CYRX 277.5M
- ALLO 371.8M
- IPO Year
- CYRX N/A
- ALLO 2018
- Fundamental
- Price
- CYRX $7.15
- ALLO $1.17
- Analyst Decision
- CYRX Strong Buy
- ALLO Strong Buy
- Analyst Count
- CYRX 8
- ALLO 10
- Target Price
- CYRX $10.75
- ALLO $9.66
- AVG Volume (30 Days)
- CYRX 470.4K
- ALLO 3.0M
- Earning Date
- CYRX 05-07-2025
- ALLO 05-13-2025
- Dividend Yield
- CYRX N/A
- ALLO N/A
- EPS Growth
- CYRX N/A
- ALLO N/A
- EPS
- CYRX N/A
- ALLO N/A
- Revenue
- CYRX $232,134,000.00
- ALLO $22,000.00
- Revenue This Year
- CYRX N/A
- ALLO N/A
- Revenue Next Year
- CYRX $8.19
- ALLO $9.07
- P/E Ratio
- CYRX N/A
- ALLO N/A
- Revenue Growth
- CYRX 11.75
- ALLO N/A
- 52 Week Low
- CYRX $4.58
- ALLO $1.09
- 52 Week High
- CYRX $16.89
- ALLO $3.78
- Technical
- Relative Strength Index (RSI)
- CYRX 68.14
- ALLO 32.50
- Support Level
- CYRX $5.43
- ALLO $1.09
- Resistance Level
- CYRX $6.00
- ALLO $1.28
- Average True Range (ATR)
- CYRX 0.49
- ALLO 0.14
- MACD
- CYRX 0.19
- ALLO -0.04
- Stochastic Oscillator
- CYRX 83.03
- ALLO 11.59
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.